We found that the panel consisting of 4 TAAs (CYFR21, CEA, NSE, and SCC) showed good diagnostic efficacy for lung cancer screening in BLD, with an AUC of 0.854 and a sensitivity of 89.4%. The gene discussed is ENO2; the disease is lung carcinoma.